Modern medical treatment of type 2 diabetes;Moderne medikamentöse Therapie des Typ-2-Diabetes

Deutsche Medizinische Wochenschrift

Volumn 139, Issue 49, 2014, Pages 2494-2497

  Hanefeld, M ^a,b   Bornstein, S R ^a,b,c,d   Barthel, A ^b,e  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Endokrinologikum Ruhr   (Germany)

Author keywords

drug therapy; guidelines; patient centered treatment; type 2 diabetes mellitus

Indexed keywords

NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HUMAN; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRACTICE GUIDELINE;

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; INSULIN DETEMIR; LONG ACTING INSULIN;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC;

EID: 84922481835     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0034-1387406     Document Type: Note

References (15)

1. Gerstein H. C., Miller M. E., Genuth S. ACCORD Study Group et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med: 2011; 364 818 828
2. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. -Langfassung, zuletzt geändert April 2014; http://www.versorgungsleitlinien.de/themen/diabetes2/dm2-therapie/pdf/nvl-t2d-therapie-lang-3.pdf (letzter Zugriff 29. September 2014)
3. Inzucchi S. E., Bergenstal R. M., Buse J. B. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia: 2012; 55 1577 1596
4. Kim H. S., Shin J. A., Lee S. H. et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther: 2013; 15 810 816
5. Mathieu C., Hollander P., Miranda-Palma B. et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab: 2013; 98 1154 1162
6. McIntosh B., Cameron C., Singh S. R. et al. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med: 2012; 6 e62 74
7. Meier J. J., Nauck M. A. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia: 2014; 57 1320 1324
8. Musso G., Gambino R., Cassader M. et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med: 2012; 44 375 393
9. Nauck M. A., Del Prato S., Durán-García S. et al. Durability of glycaemic efficacy over 2-years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab: 2014; doi 10.1111/dom.12327
10. Nauck M. A. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care: 2013; 36 2126 2132
11. Nauck M. A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med: 2011; 124 01 S3 18
12. Pozzilli P., Leslie R. D., Chan J. et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev: 2010; 26 239 244
13. Scirica B. M., Bhatt D. L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med: 2013; 369 1317 26
14. Selvin E., Steffes M. W., Zhu H. et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med: 2010; 362 800 811
15. White W. B., Cannon C. P., Heller S. R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med: 2013; 369 1327 1335